Success Metrics

Clinical Success Rate

87.4%

Based on 249 completed trials

Completion Rate

87%(249/285)

Active Trials

17(5%)

Results Posted

51%(127 trials)

Terminated

36(10%)

Phase Distribution

Ph not_applicable

Ph phase_3

12%

Ph phase_1

21%

Ph phase_4

18%

Ph phase_2

142

38%

Ph early_phase_1

Phase Distribution

Early Stage

142

Mid Stage

112

Late Stage

Phase Distribution367 total trials

Early Phase 1First-in-human

15(4.1%)

Phase 1Safety & dosage

77(21.0%)

Phase 2Efficacy & side effects

142(38.7%)

Phase 3Large-scale testing

44(12.0%)

Phase 4Post-market surveillance

68(18.5%)

N/ANon-phased studies

21(5.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.5%

249 of 302 finished

Non-Completion Rate

17.5%

53 ended early

Currently Active

trials recruiting

Total Trials

369

all time

Status Distribution

Active(23)

Completed(249)

Terminated(53)

Other(44)

Detailed Status

Completed249

unknown43

Terminated36

Withdrawn17

Recruiting10

Active, not recruiting7

Development Timeline

Analytics

Development Status

Total Trials

369

Active

Success Rate

87.4%

Most Advanced

Phase 4

Trials by Phase

Early Phase 115 (4.1%)

Phase 177 (21.0%)

Phase 2142 (38.7%)

Phase 344 (12.0%)

Phase 468 (18.5%)

N/A21 (5.7%)

Trials by Status

enrolling_by_invitation31%

unknown4312%

completed24967%

not_yet_recruiting31%

suspended10%

active_not_recruiting72%

recruiting103%

terminated3610%

withdrawn175%

Recent Activity

17 active trials

Showing 5 of 369

completedphase_3

Safety and Efficacy Study of Ferric Maltol To Treat Iron Deficiency Anaemia in Chinese Patients With Inflammatory Bowel Disease

NCT07739368

enrolling_by_invitationphase_1

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

NCT02954978

View all 369 trials

Clinical Trials (369)

Showing 20 of 369 trialsScroll for more

NCT07739368Phase 3

Safety and Efficacy Study of Ferric Maltol To Treat Iron Deficiency Anaemia in Chinese Patients With Inflammatory Bowel Disease

Completed

NCT04538755Phase 1

DAW2020 on OSA Endotypic Traits

Enrolling By Invitation

NCT05350215Phase 1

Atomoxetine and DAW2022 on OSA Severity

Recruiting

NCT03629340Phase 2

Metformin for Pulmonary Hypertension HFpEF

Completed

NCT02954978Phase 2

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

Completed

NCT04002674Phase 2

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

Completed

NCT05870111Phase 2

Citicoline in Youth Alcohol Use Disorder

Active Not Recruiting

NCT03675724Phase 2

Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults

Enrolling By Invitation

NCT07584369Phase 4

Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study

Not Yet Recruiting

NCT03430037Phase 2

Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women

Enrolling By Invitation

NCT04181996Phase 3

Canadian Study of Arterial Inflammation in Patients With Diabetes and Vascular Events: EvaluatioN of Colchicine

Completed

NCT03030248Phase 2

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

Completed

NCT03825536Phase 4

Effect of Methamphetamine on Residual Latent HIV Disease Study

Completed

NCT03850964Phase 2

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

Active Not Recruiting

NCT05288855Phase 3

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

Terminated

NCT05207085Phase 2

Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults

Recruiting

NCT03325322Phase 2

Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease

Suspended

NCT07022353Not Applicable

Bi-level Erector Spinae Plane Block and Pre-emptive Oral Tizanidine for Analgesia After Mastectomy Surgery

Completed

NCT03667326Phase 2

Postpartum Low-Dose Aspirin and Preeclampsia

Recruiting

NCT05589792Phase 1

Acetazolamide on REM OSA

Completed

Drug Details

Intervention Type: DRUG
Total Trials: 369